A recent investigation conducted by Liu et al. examined the potential of using tazemetostat, an EZH2 inhibitor, and sunitinib, an MDSC inhibitor, as therapeutic strategies to overcome immune evasion in HNSCC [92]. This evidence concerns the gene EZH2 and head and neck squamous cell carcinoma.